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This work investigated in Alzheimer’s disease dementia (AD), whether the probability of making an 
error on a task (or a correct response) was influenced by the outcome of the previous trials. We used 
the antisaccade task (AST) as a model task given the emerging consensus that it provides a promising 
sensitive and early biological test of cognitive impairment in AD. It can be employed equally well in 
healthy young and old adults, and in clinical populations. This study examined eye-movements in a 
sample of 202 participants (42 with dementia due to AD; 65 with mild cognitive impairment (MCI); 
95 control participants). The findings revealed an overall increase in the frequency of AST errors in 
AD and MCI compared to the control group, as predicted. The errors on the current trial increased in 
proportion to the number of consecutive errors on the previous trials. Interestingly, the probability 
of errors was reduced on the trials that followed a previously corrected error, compared to the trials 
where the error remained uncorrected, revealing a level of adaptive control in participants with MCI 
or AD dementia. There was an earlier peak in the AST distribution of the saccadic reaction times for 
the inhibitory errors in comparison to the correct saccades. These findings revealed that the inhibitory 
errors of the past have a negative effect on the future performance of healthy adults as well as people 
with a neurodegenerative cognitive impairment.
How do we stop ourselves doing something that we know we should not be doing, and how do our previous errors 
influence our current behaviour? A convenient way of addressing these questions in the laboratory employs the 
antisaccade task1 (AST). There is growing interest in the potential of the paradigm as a measure of inhibitory 
control in healthy and clinical populations. If we can uncover the major underlying factors that give rise to these 
errors of control in the AST, we will be in a better position to understand how these errors might be mitigated in 
various clinical and non-clinical populations to improve cognitive control. The AST presents a stimulus to the 
left or right of the screen whilst the observer is required to avoid the natural impulse to look towards the stimu-
lus, and instead to look away, to the opposite side of the screen. Healthy adults fail to inhibit the impulse to look 
towards the target on approximately 20% of trials2. The failure rate is substantially higher in AD (55–75%)3,4. In 
healthy participants, the error is usually followed shortly afterwards by a self-correcting saccadic eye movement, 
whereas these corrections occur infrequently in AD dementia, and then only after a substantial delay. The fre-
quency is positively correlated with the severity of the dementia and memory impairment3,5. To date, no study 
has attempted to track the moment-by-moment changes in cognitive control in AD dementia during the AST. 
Could there be a mechanism that resets or reboots after each error so that the system starts afresh on the current 
trial? Or is the outcome of the current trial subject to the influence of the past events? A simple way forward 
would be to examine the effect of past trials on the present trial performance. In this context, we investigated the 
extent to which the AST errors might be influenced by the outcomes of the previous trials. Tatler and Hutton6 
conducted the only study to examine the effects of historical antisaccade trials on the current trial in a sample of 
young healthy participants. This work revealed that an inhibition error on a preceding trial was strongly associ-
ated with an increase in the probability of an error on the current trial. Interestingly, the effects were not limited 
to the immediately preceding trial. They found a linear and cumulative effect of the number of past error trials on 
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the probability of an error occurring on the current trial. It is not known whether this error phenomenon is also 
found within a clinical cohort.
Several influential models of cognitive control have proposed that behavioural errors are detected on-line, 
by neural monitors (such as the Anterior Cingulate cortex) and used to adjust and correct performance on a 
moment-by-moment basis. According to Dehaene and colleagues7–9, the on-line control by neural and behav-
ioural error detection and correction networks (i.e. adaptive networks) operates primarily in the context of the 
conscious awareness of the task conflict. However, according to Miller and Cohen10 the neural network that 
includes the Anterior cingulate – Dorsolateral Prefrontal Cortex projections, is activated by the task conflict that 
is detected with or without conscious awareness. Tatler and Hutton6 found, using the AST, that the error rates 
in fact increased, rather than decreased, on the trials that followed an error on the previous trial. This seemed to 
provide little support for either of these cognitive control models. They concluded that “…an increased probabil-
ity of making an error following an error on the previous trial is opposite to the predictions made by the popular 
conflict monitoring account of antisaccade performance”p394. However, a key prediction of these models relates 
to the issue of whether or not the conflicts and errors are detected, whether consciously or unconsciously. As 
mentioned by Tatler and Hutton6, within a healthy (young) population there is little variability in the detection 
of the errors and conflict; error correction in the AST is close to 100%. Thus, young healthy participants typically 
show high error detection rates, as revealed by the very high proportion of corrective saccades. Therefore, whilst 
it is surprising that AST errors increased following a previous error, their analysis was not a critical or devastating 
test of the models. A more critical test for the models would contrast the effects of the trials in which the errors are 
detected, with the trials where the errors are not successfully detected and corrected. The cognitive control mod-
els would predict that the errors that are detected and corrected (either consciously or unconsciously according to 
Miller and Cohen10) should lead to a lower probability of errors on the following trial, in comparison to the errors 
that are not detected and corrected. This prediction can be best examined using participants with Alzheimer’s 
Disease dementia and MCI, as they are known to generate a relatively high proportion of both corrected and 
uncorrected errors. This prediction cannot be easily examined with healthy control participants who produce 
relatively few uncorrected errors in the AST.
Therefore, the following questions were addressed in this study: Do the past errors and successes have an effect 
on AD performance on the current trial? Are the inhibitory errors mediated by the speed of the reaction time on 
the current trial11? Answers to these questions will provide a more comprehensive insight into inhibitory control 
as a candidate biomarker for MCI/AD and in the monitoring of the progression of the disease.
Results
The mean and standard deviation of the participant demographic and cognitive characteristics are presented 
in Table 1. The groups did not differ with regards to gender (chi-squared test, χ2 = 2.400, p = 0.301, Cramer’s 
V = 0.077), but did differ on mean age (ANOVA, F(2,199) = 13.469, p < 0.01). As expected the dementia scores 
on MOCA differed between the groups (ANOVA, F(2,194) = 63.715, p < 0.001); where the AD group had lower 
dementia scores on the MOCA, compared to the controls & MCI; the MCI group had lower scores than the con-
trols: Table 1 also reveals that the AD and MCI groups had lower scores than the control group on reverse digit 
span, and reverse and forwards spatial span. The AD and MCI groups did not differ significantly on the reverse 
digit or the spatial span tasks.
Antisaccade task completion analyses. One hundred and sixty participants performed the complete 
sequence of 24 trials. Others had shorter sequences with no lower than 11 trials. These participants were balanced 
across the groups (chi-squared test, χ2 = 1.778, p = 0.411, Cramer’s V = 0.066). This resulted in an overall total 
of 4732 out of a possible 4848 trials, whereby the frequency of incomplete sequences was independent of the 
cognitive groups (chi-squared test, χ2 = 4.639, p = 0.098, Cramer’s V = 0.022). 79.2% of participants performed 
the full set of 24 trials and more than 95% of participants completed over 20 trials. We conducted a complete case 
-analysis (using only the 160 participants with the full 24 trials) and found no substantial differences in the overall 
pattern of the effects.
Control MCI AD ANOVA
Sex
Male 36 31 21
Female 59 34 21
Age
Mean ± SD 66.7 ± 8.6 70.5 ± 8.0 74.4 ± 7.8 F: 13.47, df: (2,199), p: <0.01, η2: 0.135
Range 48–90 56–86 57–90
MOCA Mean ± SD 27.2 ± 3.2 22.9 ± 4.4 19.7 ± 5.9 F: 20.04, df: (2,195), p: <0.01, η2: 0.256
Digit Span-F Mean ± SD 10.7 ± 2.5 10.2 ± 2.4 10.1 ± 2.4 F: 1.06, df: (2,192), p: 0.349, η2: 0.011
Digit Span-R Mean ± SD 7.2 ± 2.7 6.2 ± 2.5 5.5 ± 2.3 F: 4.88, df: (2,192), p: <0.01, η2: 0.051
Spat Span-F Mean ± SD 7.5 ± 1.4 6.7 ± 1.6 5.8 ± 1.7 F: 11.16, df: (2,180), p: <0.01, η2: 0.124
Spat Span-R Mean ± SD 6.9 ± 1.7 5.9 ± 1.9 5.5 ± 2.1 F: 4.89, df: (2,180), p: <0.01, η2: 0.054
Table 1. Participant demographic and cognitive characteristics. MOCA - Montreal Cognitive Assessment for 
Dementia; Digit Span-F – Digit Memory Span forwards assessment score; Digit Span-R – Digit Memory Span 
reverse assessment score; Spatial Span-F – Spatial Memory Span forwards assessment score; Spatial Span- R – 
Spatial Memory Span reverse assessment score.
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Are antisaccade errors increased in the AD and MCI groups compared to the controls? The 
antisaccade data can be classified into 3 types of response outcomes. Correct: a saccade is correctly directed 
into the opposite target hemifield; Error + c: an incorrect saccade directed towards the target, together with a 
later corrective saccade away from the target into the opposite hemifield; Error − c: an error with no correc-
tive saccade component. Figure 1 shows the proportion of Correct responses; errors followed by a correction 
(Error + c): and errors with no correction (Error − c) by participant group. The AD and MCI participants have 
a significantly higher proportion of Error + c and Error − c responses on the antisaccade trials in comparison 
to the control group (chi-squared test, χ2 = 193.06, p < 0.001, Cramer’s V = 0.101). The distributions of the AD 
and MCI were overlapping, consistent with the view that the MCI can be considered as a preclinical AD group. 
There was a significant effect across groups for Error − c responses with respect to the proportion of error trials: 
(chi-squared test, χ2 = 25.477, p < 0.001, Cramer’s V = 0.077) and in relation to total number of observations (i.e. 
“Errors” + “Correct”): (chi-squared test, χ2 = 86.734, p < 0.001, Cramer’s V = 0.096).
Does the probability of an error trial increase if the previous trial has been an error? Table 2 
shows the mean antisaccade errors on the current trial in relation to the outcomes of the previous trial for each 
group. A similar pattern is evident in all three groups. The numerical values represent the number and proportion 
of antisaccade errors in each category, and the log-odds ratio of the patient groups relative to the control group for 
each of the previous trial outcome events (standard errors for each estimate are presented in parentheses). Trials 
where an inhibitory error occurred, irrespective of whether this was subsequently corrected, generated a higher 
than 50% chance of resulting in a further error on the current trial (e.g. For controls with last uncorrected error 
event, one-tailed Z-test, Z-statistic: 2.23, p = 0.013; see Table 2). Figure 1 shows the error probability in relation 
to the previous trial before, and after, accounting for the individual random variability. The sample estimates (in 
grey with diamond points) do not account for subject variation and so there is over-confidence in the probability 
estimates. The estimates derived from the model (black with circle points) represent the account for individ-
ual subject variation. Despite the differences in the error probability estimates, the broad and expected patterns 
between the groups is preserved as well as the dependence on the previous AST trial.
We also addressed the inverse question: Did the probability of an error response decrease on 
the current trial, if the previous trial was a correct response? Table 2 reveals that the probability of 
an error on the current trial was significantly below 50% (chance) if the immediately preceding trial was correct 
(c). The form of the effect is very similar for the Control, MCI and AD groups (Fig. 1). Correct antisaccade trials 
are less likely to be followed by trials that incur an error on the previous trial (one-tailed Z-test, Z-statistic: −23.25 
(control), −5.87 (MCI) & −7.15 (SD), p < 0.001in each case). The log-odds ratio for correct trials between the 
Figure 1. Graph showing the mean error probability on the current trial, after accounting for random subject 
variability in relation to the outcomes on the previous trial. The sample estimates (in grey with diamond points) 
do not account for subject variation and so there is over-confidence in the probability estimates. The estimates 
derived from the model (black with circle points) do account for subject variation. Despite the differences in 
the error probability estimates, the broad and expected patterns between groups is preserved as well as the 
dependence on the last (i.e. previous) AST. −c = the previous trial was an error with no correction; +c = the 
previous trial was an error with correction; correct = the previous trial was a correct antisaccade. Mild cognitive 
impairment (MCI) and Alzheimer’s disease (AD).
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Alzheimer and control groups is statistically lower than zero irrespective of the outcome of the previous trial 
(one-tailed Z-test, Z-statistic: 3.83 (Error − c), 3.46 (Error + c) & 4.46 (correct), p < 0.001 in each case). This 
indicates that the chance of incurring an error is higher for the AD group compared to the control group. A 
similar relationship is observed for the MCI group compared to the control (one-tailed Z-test, Z-statistic: 2.92 
(Error − c), 1.79 (Error + c) & 8.13 (correct), p = 0.002, 0.037 & < 0.001 respectively).
Did the probability of an error response decrease on the current trial, if the error on the pre-
vious trial was a corrected error (Error + c vs. Error − c)? An analysis was conducted to determine 
the potential impact of the Error + c trials in comparison to the Error − c trials. Table 2 reveals that there were a 
relatively lower proportion of errors following a corrected trial (Error + c) in comparison to an uncorrected trial 
(Error − c) for both the Alzheimer’s (Z = 2.954, p = 0.003) and MCI groups (Z = 3.297, p < 0.001). It is worth 
noting that this highly significant effect benefitted the MCI and AD groups rather than the healthy control group, 
precisely those clinical groups who generate uncorrected errors. This suggests that there was a level of adaptive 
control for the clinical groups who would benefit most.
Generalised Linear Multilevel Model Analyses (GLMM) were conducted to investigate the potential impact 
arising from participant variability. The fixed effects of the best model contained the cognitive groups and the 
outcome of the previous trial. Inclusion of an interaction between these was not significant (deviance test, devi-
ance = 3.316, df: 4, p = 0.506). The inclusion of an age fixed effect was also not significant (deviance test = 2.798, 
df: 1, p = 0.094), indicating that the participant random effect captured the imbalance within the data. The 
error probability estimates (Fig. 1) confirmed the previous pattern of effects; the chance of an error AST trial 
increases across groups with increasing cognitive impairment. Moreover, the effect of a previously correct AST 
trial improves the chances of a correct behaviour on the current trial. The increased uncertainty in the probability 
estimates relate to the fact that the standard deviation of the random effect was estimated at 1.524 (bootstrap 
95% confidence interval: 1.309–1.704). The inclusion of the random effect in the model is highly significant 
(deviance test, dev = 614.742, df: 1, p < 0.001); the estimated standard deviation is larger than all of the estimated 
coefficients (see Table 3). Despite being able to identify the key trial and group dependence structure, this high 
standard deviation estimate suggests that a large proportion of the variability within the data originates within the 
individual differences in the baseline scores in the ASTs. Yet, so far the analyses have only addressed the effects 
of the immediately preceding trial (trial n-1). The subsequent analyses address the potential effects on trials n-2, 
n-3, n-4 etc. on the current trial.
Do the effects of the past outcomes in AST extend beyond the most recent trial? Are the effects 
of the previous error (or correct responses) cumulative? This section describes the effects of the 
sequence length on the correct and error trials.
Figure 2 presents the predicted probability for an average participant in each of the groups depending on the 
sequence length of the previous trials. It shows the predicted probability of errors (with shaded 95% confidence 
intervals) as a function of the number of consecutive error and correct trials. If the sequence is of correct trials, 
then the probability that the current trial is an error decreases with the sequence length for all groups, whilst this 
error probability increases for all groups in the case of an increasing sequence length of error trials.
Table 4 presents the sample proportions for a correct current trial in relation to the sequence lengths. A 
significant deviation from the sequence length of 1 (i.e. dependence on the last trial only) was found for all 
groups, where the current error sample proportions decrease with the increasing sequences of correct trials whilst 
increasing for sequences of error trials. Subject variation was accounted for by fitting a GLMM.
The optimal model, summarised in Table 4, contains cognitive group, and the number of previous correct and 
previous error trials as fixed effects. The effect of subject age was not significant (deviance test, deviance = 2.969, 
Previous Trial Control MCI AD
Error (−c)
Errors (N) 78 141 123
Proportion (se) 59.5% (0.043) 75.8% (0.031) 81.5% (0.032)
Log-odds (se) — 0.756 (0.259) 1.094 (0.286)
Error (+c)
Errors (N) 362 374 262
Proportion (se) 57.4% (0.020) 62.5% (0.020) 68.6% (0.024)
Log-odds (se) — 0.216 (0.121) 0.484 (0.140)
Correct
Errors (N) 319 260 140
Proportion (se) 23.4% (0.011) 38.9% (0.019) 33.5% (0.023)
Log-odds (se) — 0.737 (0.091) 0.502 (0.112)
Error (−c) vs. Error (+c)
Log-odds (se) 0.089 (0.195) 0.629 (0.191) 0.699 (0.237)
Z-statistic (p-value) 0.458 (0.647) 3.297 (<0.001) 2.954 (0.003)
Table 2. The effect of the previous trial on the current trial. se – standard error.
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df: 1, p = 0.085), nor was there a significant interaction between the covariates (deviance test, deviance: 1.250, 
df: 4, p = 0.870). This provides no evidence that the slopes are significantly different between the groups. The 
inclusion of the random effect had a significant effect (deviance test, deviance: 259.024, df: 1, p = <0.001) with a 
participant standard deviation of is 1.374 (bootstrap 95% confidence interval: 1.175–1.543).
These analyses support a common principle that increases the probability of an error on the current trial. Past 
consecutive errors and correct responses predict future error and successes respectively. Apparently, the effect is 
cumulative. This principle applies to people with and without dementia. What distinguished the groups was not 
the principle, but the scaling of the effect. The higher the proportion of consecutive past errors, the more likely it 
is that the current trial will be an error. People with dementia commit more overall errors as a consequence of the 
disease. Importantly, the effects are already evident at the early MCI stage of the disease.
Variable Estimate (Log-odds) Std. Error Z value P value
Intercept
Control Group 0.741 0.164 4.534 <0.001
MCI Group −0.200 0.189 −1.059 0.290
Alzheimer Group −0.344 0.236 −1.455 0.146
Slope
No. Previous Success 0.047 0.018 2.666 0.008
No. Previous Fail −0.040 0.020 −2.028 0.043
Table 3. GLMM fixed effect estimates for the dependence of antisaccade error trials (i.e. incorrect prosaccade) 
on the sequence length of previous correct or error trials. Participant random effect standard deviance estimate 
is 1.374 (95% confidence interval: 1.175–1.543).
Figure 2. Predicted probability for an average participant in each group depending on the sequence length of 
the previous trials. Red = control; Green = Mild Cognitive Impairment; Blue = Alzheimer’s groups.
Length
Correct sequence Error Sequence
Control MCI AD Control MCI AD
1 0.354 0.504 0.461 0.436 0.521 0.588
2 0.300 0.439 0.462 0.510 0.582 0.532
3 0.279 0.314** 0.317 0.771** 0.683** 0.837**
4 0.130** 0.370 0.077** 0.765** 0.704* 0.825**
5 0.227* 0.192** 0.174* 0.795** 0.757** 0.800*
6+ 0.101** 0.136** 0.153** 0.792** 0.893** 0.903**
Table 4. Proportion of error antisaccade trials, by participant group, for various lengths of immediately 
preceding and consecutive correct or error trials. Asterisk denotes proportions that are significantly different 
from the corresponding length 1 proportion at the 5% (*) and 1% (**) levels. (Two-tailed Z-test applied to the 
corresponding log-odds ratio estimates).
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Is there a common underlying mechanism for errors and correct antisaccades? Race models 
predict a strong relationship between the reaction time of the antisaccade response and the probability of a cor-
rect saccade2,11. Given that volitional saccades require a longer programming time, faster latencies will allow less 
time for the competing volitional saccade to be generated. Longer reaction times will increase the time for the 
volitional neural activation of the neural signal to reach the threshold for activating the saccade. If this process 
applies equally to the brain with and without dementia, then we would predict that the reaction time plots in 
relation to error and error responses would be isometric and overlapping, irrespective of the clinical condition. 
We will return to this point in the discussion section.
Figure 3 presents the Kaplan-Meier plot of the survivor curves for participant reaction time. This describes the 
proportion of participants who are yet to record a saccadic event (correct saccade vs error saccade) at the given 
duration of time. It is immediately apparent that the trials that result in a correct antisaccade have longer reaction 
times than those trials with an error. Any differences in reaction time between cognitive groups are only subtle. 
As the distribution of reaction times was asymmetric, the responses were transformed onto the log scale prior 
to modelling. The difference in reaction time with regards to the trial outcome remained significant on this scale 
(Welch two sample t test, t = −37.454, df: 4364, p < 0.001; Cohen’s d = 1.118, R-squared = 0.243). Table 5 shows 
the median latencies and 95% confidence intervals for the correct and incorrect trials. The relative latency dif-
ference between correct and incorrect antisacades was remarkably similar across the groups (Controls = 104 ms; 
MCI = 92 ms; AD = 106 ms).
Discussion
A growing number of studies have demonstrated that endogenous saccadic eye movements (i.e. antisaccades) are 
highly sensitive to the impairment of cognitive control in the AD group, and the reflects to some extent the dys-
function of working memory and inhibitory control5,11,12. However, this is the first study in AD to investigate the 
effects of the past trials on the behaviour of the current trial. We employed the AST to examine this, as this simple 
task is well tolerated by people with dementia and yields a frequency distribution of correct and error responses 
in patients and healthy controls. The following questions were under investigation: To what extent did an error 
(or correct saccade) on the previous trial influence the outcome on the current trial? Is there a cumulative effect of 
the past errors (or correct saccades) on the current behaviour? What is the relationship between AST errors and 
saccade reaction times? The findings were clear and compelling. A previous error or a consecutive sequence of 
errors increased the probability of an error on the current trial. Conversely, a correct saccade on the previous trial 
increased the probability of a correct response in the future. The effects were cumulative with longer sequences 
of errors (or corrections) predicting a proportionally higher probability of future errors (or corrections). The 
current findings are consistent with the previous work on healthy young adults, which reported a similar effect2 
(Tatler & Hutton, 2006). Interestingly, the errors were significantly reduced on the trials that followed a previously 
corrected error, compared to trials where the error remained uncorrected, revealing a level of adaptive control 
in participants with early dementia. This indicates that participants with early (MCI) or a later stage of dementia 
(AD) retain a level of adaptive cognitive control that may help to modulate the errors. This effect was not signif-
icant for the control group when analysed in isolation, probably due to the well-known low level of uncorrected 
errors in healthy controls.
Figure 3. Kaplan-Meier plot of the reaction time survival curves. Dashed – correct antisaccade trials; Solid – 
Error antisaccade trials (irrespective of whether the error was corrected or not). Red - Control; Green – MC; 
Blue – Alzheimer.
Initial event Control MCI Alzheimer
Correct 280 (276–286) 278 (270–286) 294 (282–306)
Error 176 (172–180) 186 (182–192) 188 (180–194)
Table 5. Median reaction time and 95% confidence interval of the median estimate.
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It is worth considering the potential factors that could have given rise to the cumulative effects of the AST 
errors. According to the race competition models of the AST a “race” commences, at the onset of the target, 
between the exogenously triggered prosaccade and the endogenous antisaccade signal11. The signal that first 
reaches the threshold “wins” the competition and triggers the saccade. The threshold of activation for either of 
the two competing signals can be modified by modulating the rate at which activation of the neural signal rises 
to the threshold, or the baseline level of activation before the stimulus onset13–15. Therefore, one possibility is that 
there is a persistent and stable increase in the baseline level of activation in the exogenous (i.e. prosaccade) and/
or a decrease in the baseline of the endogenous (antisaccade) signal across the trials6 giving rise to the increased 
errors. In this way, with each additional error in the sequence, a growing tendency emerges towards further 
errors. Relatively fast reaction times are associated with the errors (i.e. prosaccade) in comparison to the correct, 
but slower antisaccade, as revealed in Fig. 3. Keeping in mind the fact that the frequency of the uncorrected 
errors was also greater in participants with dementia, this may be due to an additional problem with the internal 
monitoring of action that appears to be compromised in AD. This is in contrast to participants with Parkinson’s 
disease and schizophrenia , whose errors are usually associated with a subsequent rapid and spontaneous error 
correction3,16.
Another possible explanation can be derived from our work on the effects of glucose and motivation on 
antisaccades17. A number of studies have shown that individuals find it difficult to complete two consecutive 
self-control tasks that require cognitive effort; the first is completed as usual, but there is usually a decline in per-
formance on the second task18. One influential theory19 states that this decline stems from a depletion in the lim-
ited resources of self-control, since the effect is specific to self-control tasks and not found for automatic tasks18,20. 
Since glucose was claimed to be the source of this critical energy, we hypothesised that a glucose supplement 
should be able to mitigate against this decline in self-control21. Our results did not support this theory. Using a 
double-blind study, we found that glucose did not protect the antisaccade performance following a Stroop task. 
However, there was a strong effect of the motivation level on the AST errors. High levels of motivation were asso-
ciated with a low frequency of AST errors. Therefore, given that the motivation levels mediated the AST errors in 
the Kelly et al.17 study, it is conceivable in the current work that motivation levels may also have been associated 
with the frequency of errors. One can imagine a descending cascade where an error leads to the depletion of moti-
vation, which then leads to a further error. This cascade could be a mediating factor in the accumulative effects 
of the AST errors. A consecutive sequence of successful correct saccades may have protected against the decline 
in task motivation, in contrast to a series of failures, which would be more likely to have fostered a lower level of 
motivation. Clearly, further work will be required to evaluate the validity of this hypothesis.
Inferences that are derived from the neurocognitive work on Alzheimer’s disease have often been contingent 
on a number of assumptions in relation to the participant’s performance on the cognitive task. For example, 
there is an assumption that the participant has a full understanding of the task and is sufficiently motivated to 
perform well. A major appeal of the saccadic eye movement paradigms is that these can be applied irrespective 
of a verbal or somatomotor dysfunction, and therefore can be used for the assessment of cognition across a wide 
range of domains including clinical, animal neurophysiological and infancy research2,22. The sessions are kept 
as short as possible to protect against the loss of concentration and motivation. We use a blocked presentation of 
trials design and we started each testing session with the AST to avoid the well-known priming effects from the 
prosaccade task. Note also the selective nature of the eye-tracking impairments in AD. For example, participants 
with AD dementia performed remarkably similar to controls in an attentional disengagement saccade overlap 
task23 which demonstrates that prosaccadic eye movement paradigms are unlikely to be inherently cognitively 
demanding for these participants. This increases our confidence that the patients understood the antisaccade task 
and were motivated to perform well, given the evidence that on a high proportion of the trials, the errors were 
self-corrected.
In considering the impairment of saccadic eye movements in AD group it is important highlight again its 
selective nature given that a number of keys features were in fact, well preserved. For example, prosaccade ampli-
tudes, peak velocity and the attentional disengagement (measured by the GAP effect) were preserved and remain 
stable over time3,23. The current work revealed that inhibitory control in AD was influenced by the past perfor-
mance in a similar fashion to the healthy controls. Similarly, errors were associated with faster reaction times in a 
similar manner to the control group. These findings revealed that there is no fundamental change in the principles 
that govern the regulation of AST errors in people with dementia. Apparently, the dementia status adds a positive 
constant to the AST errors but there is a common underlying principle in relation to the effect of past error and 
success on the current behaviour.
Methods and Materials
Two hundred and two participants were included in this study: 42 with dementia due to Alzheimer’s disease 
(AD) and 65 with mild cognitive impairment (MCI); Control participants were 95 volunteers who were either the 
spouses of the AD or MCI participants or were research volunteers from the North West of the UK. Participants 
with dementia were referred and diagnosed via memory clinics in the United Kingdom National Health Service 
after a comprehensive evaluation by the dementia assessment team. The participants were all white British or 
European with a minimum of 11 years of education and fluent in the English Language (age and gender character-
istics are shown in Table 1). Participants with a diagnosis of dementia due to AD satisfied the NINCDS-ADRDA 
criteria24. The following criteria were required for the diagnosis of MCI25: (1) a subjective complaint of a decline in 
memory function (that was confirmed by the individual or his/her informant/primary care giver); (2) an objective 
impairment using a formal memory test or other cognitive impairment (where the scores on the standard cogni-
tive tests were at least 1.5 SDs below the age-adjusted adjusted norms); (3) a relative preservation in the activities 
of daily living. The following exclusion criteria were applied: a previous history of head trauma, stroke, cardiovas-
cular disease, active or past alcohol or substance misuse/dependence, or any physical or mental condition severe 
8Scientific RepoRtS |         (2019) 9:20204  | https://doi.org/10.1038/s41598-019-56625-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
enough to interfere with their ability to participate in the study. All participants had the capacity to consent to 
participation in the study and gave signed informed consent. The study received ethical approval from the local 
NHS Research Ethics Committee, NHS Health Research Authority and Lancashire Care Teaching Hospital Trust. 
These experiments were performed in accordance with the UK British Psychological Society ethical guidelines.
Stimuli and Tasks. Apparatus. Eye movements were recorded using the EyeLink Desktop 1000 eye-tracker 
(SR Research) sampling at 500 Hz. Participants were seated 55 cm away from the display monitor (60 Hz). The 
Miles test (Roth, Lora and Heilman (2002)) was used to determine the dominant eye and tracked accordingly. The 
raw data was exported from the EyeLink to the DataViewer software and analysed offline with bespoke software26. 
To filter noise and spikes all frames were removed where the velocity signal was greater than 1,500 deg/s or the 
acceleration signal was greater than 100,000 deg2/sec. The latency of the saccade was measured from the onset 
of the saccade to the target onset. Fixations and saccadic events were detected using the EyeLink parser which 
filtered out anticipatory saccades (i.e. saccades which were programmed before the presentation of the distractor) 
and excessively delayed saccades (due to inattention) using a temporal window of 80–700 ms measured from 
the onset of the target.
Antisaccade task (AST). Each trial was preceded by a 1 second instruction screen stating that the participant 
should look away from the target. A central fixation target was displayed in white on a black background. This 
was displayed for one second. There was a 200 ms blank interval before the appearance of the saccade target. The 
saccade target (in red) was then presented in a random order 4 degrees away from the fixation target on the left 
or right side for 2 seconds. Participants were asked to fixate on the central fixation spot and then to generate the 
saccade to the opposite side of the screen as soon as the target appeared on the display (Fig. 4). We introduced 
several procedures to increase the compliance of the dementia groups. Each trial was preceded by an instruction 
screen that clearly explained to the participant how to direct the eyes on an antisaccade trial. Extensive pilot work 
in our lab has revealed that participants with AD can tolerate a limited number of trials without loss of concen-
tration and mental fatigue. Therefore, in order to reduce the effects of experimental fatigue we restricted the AST 
to 24 trials.
Cognitive assessment. The Dementia Assessment: Montreal Cognitive Assessment27 is a brief screening tool for 
Alzheimer’s dementia that includes the cognitive functions of attention and concentration, executive control, 
memory, language, visuo-constructional skill, conceptual thinking, calculation and orientation. A score between 
0–25 (max = 30) is considered to be within the dementia range.
The digit span task28 assesses phonological memory function; participants were presented verbally with a set 
of single digit numbers and required to recall the digits in the correct serial order. The number of digits gradually 
increased during the course of the experiment, starting with two and going up to a maximum of eight. Two trials 
were presented at each level of difficulty and a participant must get both correct in order to progress to the next 
level. Participants were then presented with a reverse digit span task, where they were required to name the items 
in the reverse order of the presented sequence. Again, the number of digits were presented incrementally, from 
two to eight. Two trials were presented at each level, both needed to be correct in order for the participant to pro-
gress. A total digit span score was then calculated out of 16 for each of the forward and reverse digit spans tests.
In the spatial span task29 participants were presented with a board containing an irregular array of nine square 
blocks. The experimenter pointed to each block, one block at a time in a given pseudo-randomised sequence. 
At the end of the sequence, the participant was required to point to each of the blocks that were indicated in the 
correct serial order. The number of square blocks selected in a sequence was increased over the course of the 
experiment, from two up to a maximum of eight. Two trials were presented at each level and the participant had 
to achieve both correct in order to progress to the next level. A reverse version of the task was also conducted with 
the participant indicating the sequence in the reverse order. A total spatial span score was then calculated out of 
16 for each of the forward and reverse forms of the tests.
Statistical analysis. The principal aim of these analyses was to search for any evidence that the outcome of 
the current trial (error vs. success) and/or the reaction times was predicated on the outcome of previous trial(s), 
the participant’s cognitive grouping or another explanatory variable. It is important to take into account each 
Figure 4. Standard prosaccade task (PST) showing the eye directed towards the green target. In the antisaccade 
task (AST) the eye is directed away from the target to the opposite hemifield.
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participant’s predisposition for a particular outcome. Any given set of participants may have very different natural 
error rates irrespective of their group membership or demographic status. Accounting for specific effects at the 
level of each individual recognises that the trials are nested within a participant, and consequently enables a better 
quantification of the main effects of interest. This was achieved using multilevel models, also known as hierarchi-
cal linear model or random coefficient models30–32.
Two dependent variables for the eye-tracking tasks were entered into these analyses: the trial outcome (i.e. 
whether or not an inhibitory error was committed in the AST: error or correct); and the saccade reaction times 
after the appearance of the “distractor” for the errors and the correct responses. Let yi,j denote the trial outcome 
for participant i at trial j, which describes a Bernoulli trial that takes the value 1 for an inhibitory control error and 
0 for a correct saccade. The trial probability for an AST error pi,j, is mapped to the real-line using the logit trans-
form, µ = logit(p )i,j
(y)
i,j , which is then characterised by the linear predictor of explanatory variables given in Eq. (1) 
below. For the second response, we denote ti,j as the log of the reaction time for participant i at trial j. The reaction 
times are transformed onto the log-scale to reduce the asymmetry in the measurements. These measurements can 
be described using the linear regression model = µ +t ei,j i,j
(t)
i,j where the predictor, µi,j
(t), is a linear function of 
explanatory variables (Eq. (1)) and ei,j is the residual error associated with each observation. The predictors µi,j
(y) 
and µi,j
(t) are linear functions of the explanatory variables and the participant specific effects. In general, the linear 
predictor is defined to be:
µ β β β= + + + + …u x x (1)i j i i j i j, 0 1 1, , 2 2, ,
where …x , x ,1,i,j 2,i,j  denote the explanatory variables (e.g. cognitive group, age, gender, last trial outcome, etc.) 
and β β β …, , ,0 1 2  are the co-efficients of the main effect that are to be estimated. The decision on which explana-
tory variables were significant and included into each model was determined by using a backwards-variable selec-
tion with the deviance hypothesis test. The random quantity ui represents participant i’s deviation from the overall 
baseline value, β0. These subject effects are assumed to follow a zero-mean normal distribution with unknown 
variance to be estimated. All of the analyses were conducted in R statistical software33 using the “lme4” pack-
age34,35 for inference for the linear and generalised linear multilevel models (GLMM). The additional package 
“survival”36,37 was used to evaluate and summarise the reaction time survival curves in Fig. 3.
Data availability
The data supporting the conclusions of this manuscript will be made available by the authors, without undue 
reservation, to any qualified researcher on reasonable request.
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